Triple Negative Breast Cancer

被引：36
|
作者：
Cetin, Idil [1 ]
Topcul, Mehmet [2 ]
机构：
[1] Istanbul Univ, Fac Sci, Dept Radiobiol, Istanbul, Turkey
[2] Istanbul Univ, Fac Sci, Dept Biol, Istanbul, Turkey
来源：
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2014年 / 15卷 / 06期
关键词：
Triple negative breast cancer; poor prognosis; targeted therapy; ENDOTHELIAL GROWTH-FACTOR; FACTOR RECEPTOR; MOLECULAR SUBTYPES; RISK-FACTORS; STEM-CELLS; PROGNOSTIC VALUE; BASAL; CHEMOTHERAPY; CARCINOMA; SURVIVAL;
D O I：
10.7314/APJCP.2014.15.6.2427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed. This mini-review focuses on discovery of new targets and drugs which might offer new hope for TNBC patients.
引用
收藏
页码：2427 / 2431
页数：5
相关论文
共 50 条
  • [41] Peritumoural vascular invasion: A major determinant of triple-negative breast cancer outcome
    Sabatier, Renaud
    Jacquemier, Jocelyne
    Bertucci, Francois
    Esterni, Benjamin
    Finetti, Pascal
    Azario, Francine
    Birnbaum, Daniel
    Viens, Patrice
    Goncalves, Anthony
    Extra, Jean-Marc
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (10) : 1537 - 1545
  • [42] Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment
    Li, Yuan
    Kong, Xiangyi
    Wang, Zhongzhao
    Xuan, Lixue
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (05) : 1351 - 1362
  • [43] The prognostic value of tumour-stroma ratio in triple-negative breast cancer
    Moorman, A. M.
    Vink, R.
    Heijmans, H. J.
    van der Palen, J.
    Kouwenhoven, E. A.
    EJSO, 2012, 38 (04): : 307 - 313
  • [44] Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
    Loizides, Sotiris
    Constantinidou, Anastasia
    FRONTIERS IN GENETICS, 2023, 13
  • [45] Triple-negative breast cancer and the potential for targeted therapy
    Jhan, Jing-Ru
    Andrechek, Eran R.
    PHARMACOGENOMICS, 2017, 18 (17) : 1595 - 1609
  • [46] Mesothelin (MSLN) is Highly Expressed in Triple Negative Breast Cancer and is Associated with Enhanced Cell Proliferation and Proinflammatory Tumor Microenvironment
    Hagerty, Brendan L.
    Sato, Takumi
    Wu, Rongrong
    Ishikawa, Takashi
    Takabe, Kazuaki
    ANNALS OF SURGICAL ONCOLOGY, 2025, : 4476 - 4486
  • [47] Immunotherapeutic interventions of Triple Negative Breast Cancer
    Zehuan Li
    Yiran Qiu
    Weiqi Lu
    Ying Jiang
    Jin Wang
    Journal of Translational Medicine, 16
  • [48] Immunotherapeutic interventions of Triple Negative Breast Cancer
    Li, Zehuan
    Qiu, Yiran
    Lu, Weiqi
    Jiang, Ying
    Wang, Jin
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [49] Metabolic characterization of triple negative breast cancer
    Cao, Maria D.
    Lamichhane, Santosh
    Lundgren, Steinar
    Bofin, Anna
    Fjosne, Hans
    Giskeodegard, Guro F.
    Bathen, Tone F.
    BMC CANCER, 2014, 14
  • [50] IMMUNOHISTOCHEMICAL DIFFERENTIATION OF TRIPLE NEGATIVE BREAST CANCER
    Lesar, Miroslav
    Stanec, Mladen
    Lesar, Nikola
    Vrdoljak, Danko Velimir
    Zore, Zvonimir
    Bavnovic, Marija
    Brozovic, Gordana
    ACTA CLINICA CROATICA, 2016, 55 (01) : 3 - 8
12345